Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia

American Journal of Hypertension

Volumn 12, Issue 7, 1999, Pages 673-681

  Papadakis, John A ^a   Ganotakis, Emmanuel S ^a   Jagroop, Indera A ^a   Mikhailidis, Dimitri P ^a   Winder, Anthony F ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antihypertensives; Bilirubin; Cardiovascular risk; Dyslipidemia; Fibrinogen; Lipoprotein(a)

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FIBRINOGEN; GLUCOSE; INDAPAMIDE; LIPID; LIPOPROTEIN A; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LIPOPHILICITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BILIRUBIN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SMOKING;

EID: 0033000175     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(99)00049-7     Document Type: Article

References (59)

1. Castelli W.P., Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 80:1986;23-32.
2. Assmann G., Schulte H., Cullen P. New and classical risk factors the Munster heart study (PROCAM) . Eur J Med Res. 2:1997;237-242.
3. Kannel W.B. Cardioprotection and antihypertensive therapy the key importance of addressing the associated coronary risk factors (the Framingham experience) . Am J Cardiol. 77:1996;6-11.
4. Flack J.M., Neaton J., Grimm R. Jr, et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation. 92:1995;2437-2445.
5. Benderly M., Graff E., Reicher-Reiss H., Behar S., Brunner D., Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Throm Vasc Biol. 16:1996;351-356.
6. Breimer L.H., Ganotakis E.S., Mikhailidis D.P. Fibrinogen as a cardiovascular risk factor. Rev Port Cardiol. 16:1997;245-250.
7. Ernst E., Resch K.L. Fibrinogen as a cardiovascular risk factor a meta-analysis and review of the literature . Ann Intern Med. 118:1993;956-963.
8. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridaemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 77:1996;1179-1184.
9. Dahlen G.H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 108:1994;111-126.
10. Hopkins P.N., Wu L.L., Hunt S.C., James B.C., Vincent G.M., Williams R.R. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscl Throm Vasc Biol. 16:1996;250-255.
11. Mikhailidis D.P., Ganotakis E.S. Plasma albumin and platelet function relevance to atherogenesis and thrombosis . Platelets. 7:1996;125-137.
12. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 333:1995;1301-1307.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
14. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
15. Ding Y.A., Chou T.C., Lin K.C. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens. 8:1994;273-278.
16. Middeke M., Richter W.O., Schwandt P., Holzgreve H. The effects of antihypertensive combination therapy on lipid and glucose metabolism hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril . Int J Clin Pharmacol Ther. 35:1997;231-234.
17. Grimm R.H. Jr, Flack J.M., Grandits G.A., et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA. 275:1996;1549-1556.
18. Catalano M., Cislaghi C., Carzaniga G., Aronica A., Seregni R., Libretti A. Effects of treatment with verapamil SR and captopril on the lipid profile of hypertensive patients. Drugs. 44:(suppl 1):1992;88-93.
19. Levy D., Walmsley P., Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT) a multicenter study of doxazosin in patients with hypertension . Am Heart J. 131:1996;966-973.
20. 1 inhibition with doxazosin in hypertensive smokers and non-smokers haemodynamic and metabolic effects . J Hypertension. 8:(suppl 5):1990;S41-S46.
21. Fogari R., Zoppi A., Malamani G.D., Marasi G., Vanasia A., Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharm. 39:1995;471-476.
22. Schlueter W., Keilani T., Batlle D.C. Metabolic effects of converting enzyme inhibitors focus on the reduction of cholesterol and lipoprotein(a) by fosinopril . Am J Cardiol. 72:1993;37-44.
23. Feuerstein G.Z., Bril A., Ruffolo R.R. Jr. Protective effects of carvedilol in the myocardium. Am J Cardiol. 80:1997;41-45.
24. Bartosz M., Kedziora J., Bartosz G. Antioxidant and prooxidant properties of captopril and enalapril. Free Radical Biol Med. 23:1997;729-735.
25. Raij L., Hayakawa H., Coffee K., Guerra J. Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. Am J Hypertens. 10:1997;1257-1262.
26. Boucher F.R., Schatz C.J., Guez D.M., de Leiris J.G. Beneficial effect of indapamide in experimental myocardial ischemia. Am J Hypertens. 5:1992;22-25.
27. Stone N.J. Secondary causes of hyperlipidaemia. Med Clin N Am. 78:1994;117-141.
28. Frati C., Bevilaqua L., Apostolico V. Association of etretinate and fish oil in psoriasis therapy. Inhibition of hypertriglyceridemia resulting from retinoid therapy after fish oil supplementation. Acta Dermato-Venereologica. 186:(suppl):1994;1511-1513.
29. Mikhailidis D.P., Spyropoulos K.A. The effect of tamoxifen on lipid and haemostatic predictors of ischaemic heart disease. J Drug Dev Clin Pract. 8:1996;19-24.
30. Montgomery H.E., Clarkson P., Nwose O.M., et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arterioscler Thromb Vasc Biol. 16:1996;386-391.
31. Rosengren A., Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. The study of men born in 1933. J Intern Med. 239:1996;499-507.
32. Grines C.L., Topol E.J., O'Neill W.W., et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation. 91:1995;298-303.
33. Howard B.V., Le N.A., Belcher J.D., et al. Concentrations of Lp(a) in black and white young adults relations to risk factors for cardiovascular disease . Ann Epidemiol. 4:1994;341-350.
34. Schreiner P.J., Morrisett J.D., Sharrett A.R., et al. Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Throm Vasc Biol. 13:1993;826-833.
35. Mikhailidis D.P., Papadakis J.A., Ganotakis E.S. Smoking, diabetes and hyperlipidaemia. J Roy Soc Health. 118:1998;91-93.
36. Lomas J., Anderson G.M., Domnick-Pierre K., Vayda E., Enkin M.W., Hannah W.J. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 321:1989;1306-1311.
37. Mann K.V., Putnam R.W. Barriers to prevention ideal versus actual practices in reducing cardiovascular risk . Can J Family Med. 36:1990;665-670.
38. Flack J.M., Novikov S.V., Ferrario C.M. Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J. 17:(suppl A):1996;16-20.
39. Julius S. Current trends in the treatment of hypertension a mixed picture . Am J Hypertens. 10:(suppl):1997;300S-305S.
40. Papadakis J.A., Mikhailidis D.P. Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension. Hospital Medicine. 59:1998;825.
41. Fogari R., Zoppi A., Lazzari P., Preti P., Mugellini A., Corradi L., Lusardi P. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol. 32:1998;616-620.
42. Jagroop I.A., Papadakis J.A., Mikhailidis D.P. Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet function in essential hypertension. Platelets. 9:1998;395-396.
43. Tsagadopoulos D., Antonakoudis H., Makris T., et al. Effect of antihypertensive treatment on lipids and fibrinogen Greek multicentre study of cilazapril . Cardiology. 87:1996;524-528.
44. Haenni A., Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Metabolism. 45:1996;1221-1229.
45. Frishman W.H. Clinical perspective on celiprolol cardioprotective potential . Am Heart J. 121:1991;724-729.
46. Kario K., Matsuo T., Imiya M., et al. Close relation between lipoprotein(a) levels and atherothrombotic disease in Japanese subjects > 75 years of age. Am J Cardiol. 73:1994;1187-1190.
47. Van Wersch J.W. The behaviour of lipoprotein(a) in patients with various diseases. Scand J Clin Lab Invest. 54:1994;559-562.
48. Almenar L., Osa A., Palencia M., Flores A., Sanchez E. Effects of fosinopril on the blood pressure and lipid profile of patients undergoing heart transplantation. J Heart Lung Transpl. 16:1997;454-459.
49. Gansevoort R.T., Heeg J.E., Dikkeschei F.D., de Zeeuw D., de Jong P.E., Dullaart R.P. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transpl. 9:1994;244-250.
50. Hong Y., Dahlen G.H., Pedersen N., Heller D.A., McClearn G.E., de Faire U. Potential environmental effects on adult lipoprotein(a) levels results from Swedish twins . Atherosclerosis. 117:1995;295-304.
51. Bohlen L.M., de Courten M., Hafezi F., Shaw S., Riesen W., Weidmann P. Insulin sensitivity and atrial natriuretic factor during beta-receptor modulation with celiprolol in normal subjects. J Cardiovasc Pharmacol. 23:1994;877-883.
52. Johnston G.D., Vyssoulis G., Feely J., Holden R.D., Radley D.R. Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives a randomised double-blind long-term parallel group trial . J Hum Hypertens. 9:1995;123-129.
53. Saku K., Liu K., Takeda Y., Jimi S., Arakawa K. Effects of lisinopril and bisoprolol on lipoprotein metabolism in patients with mild-to-moderate essential hypertension. Clin Ther. 17:1995;1136-1146.
54. Parik T., Allikmets K., Teesalu R., Zilmer M. Evidence for oxidative stress in essential hypertension perspective for antioxidant therapy . J Cardiovasc Risk. 3:1996;49-54.
55. Tse W.Y., Maxwell S.R., Thomason H., et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens. 8:1994;843-849.
56. 1-adrenergicantihypertensive agent. Am J Hypertens. 7:1994;159-167.
57. Fernandes A.C., Filipe P.M., Freitas J.P., Manso C.F. Different effects of thiol and nonthiol ace inhibitors on copper-induced lipid and protein oxidative modification. Free Radical Biol Med. 20:1996;507-514.
58. Ferro C.J., Webb D.J. Endothelial dysfunction and hypertension. Drugs. 53:(suppl 1):1997;30-41.
59. Jenkins R.R., Del Signore C.M., Sauer P., Skelly C. The effect of beta blocking drugs on lipid peroxidation in rat heart in vitro. Lipids. 27:1992;539-542.